Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries

Intensive Care Med. 2015 Feb;41(2):371-2. doi: 10.1007/s00134-014-3586-z. Epub 2014 Dec 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / blood
  • Antifungal Agents / therapeutic use
  • Burns / complications
  • Burns / drug therapy*
  • Candidiasis, Invasive / drug therapy*
  • Critical Care
  • Critical Illness
  • Echinocandins / administration & dosage*
  • Echinocandins / blood
  • Echinocandins / therapeutic use
  • Female
  • Humans
  • Lipopeptides / administration & dosage*
  • Lipopeptides / blood
  • Lipopeptides / therapeutic use
  • Male
  • Micafungin
  • Middle Aged
  • Wound Infection / drug therapy*
  • Young Adult

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Micafungin